Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temferon in Early Relapsed Multiple Myeloma
NCT03875495Phase 2Terminated
- Sponsor
- Genenta Science
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Temferon in multiple myeloma (MM), sponsored by Genenta Science. Started Mar 2019; status: terminated.
02
Drugs
Temferon
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03875495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875495.